Spots Global Cancer Trial Database for breast cancer metastatic
Every month we try and update this database with for breast cancer metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients | NCT04556292 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | SC10914 | 18 Years - | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research | NCT03132506 | Breast Cancer M... | patient-reporte... | 18 Years - 80 Years | University Women's Hospital Tübingen | |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | NCT03742245 | Breast Cancer M... Breast Cancer | Olaparib Vorinostat | 18 Years - | The Methodist Hospital Research Institute | |
| Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer | NCT03002532 | Breast Cancer M... Brain Metastase... | whole brain rad... | 18 Years - 75 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT03709082 | HER2-positive B... Breast Cancer M... | Palbociclib 75m... Letrozole 2.5mg T-DM1 Palbociclib 100... Palbociclib 125... Palbociclib | 18 Years - | University of Kansas Medical Center | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| Personalised Disease Monitoring in Metastatic Breast Cancer | NCT04597580 | Breast Cancer M... Estrogen Recept... | 18 Years - | The Christie NHS Foundation Trust | ||
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer | NCT05033769 | Breast Cancer F... Neoplasm, Breas... Breast Cancer M... | Eribulin Inject... Paclitaxel inje... | 18 Years - | Institut fuer Frauengesundheit | |
| Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation | NCT04368442 | Breast Cancer M... | 20 Years - | Samsung Medical Center | ||
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. | NCT05155566 | Breast Cancer M... | 18 Years - | Pfizer | ||
| HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | NCT03322215 | Breast Cancer M... | Palbociclib Fulvestrant Capecitabine | 18 Years - | Karolinska University Hospital | |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | NCT04603183 | Breast Cancer M... | Abemaciclib Paclitaxel Letrozole Fulvestrant | 18 Years - | MedSIR | |
| Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation | NCT04368442 | Breast Cancer M... | 20 Years - | Samsung Medical Center | ||
| Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer | NCT05609903 | Breast Cancer M... | Atezolizumab in... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer | NCT03045653 | Breast Cancer M... | Tamoxifen Oral ... | 18 Years - 70 Years | Sun Yat-sen University | |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | NCT04603183 | Breast Cancer M... | Abemaciclib Paclitaxel Letrozole Fulvestrant | 18 Years - | MedSIR | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| Radiotherapy for Extracranial Oligometastatic Breast Cancer | NCT04646564 | Breast Cancer M... | standard of car... radiotherapy + ... | 18 Years - 70 Years | ChineseAMS | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer | NCT05033769 | Breast Cancer F... Neoplasm, Breas... Breast Cancer M... | Eribulin Inject... Paclitaxel inje... | 18 Years - | Institut fuer Frauengesundheit | |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics | NCT04047459 | Breast Cancer M... | Tissue samples ... | 18 Years - 65 Years | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease | NCT05800275 | Leptomeningeal ... Leptomeningeal ... HER2-positive M... | Tucatinib Oral ... Capecitabine ta... Trastuzumab Inj... | 18 Years - | UNICANCER | |
| A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients | NCT04556292 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | SC10914 | 18 Years - | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | |
| Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | NCT05301530 | Breast Cancer M... Breast Cancer F... Breast Cancer R... | Faceptor Herceptin Docetaxel | 18 Years - 65 Years | Nanogen Pharmaceutical Biotechnology Joint Stock Company | |
| Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients | NCT03328884 | Breast Cancer M... | Irinotecan Hydr... | 18 Years - | MedSIR | |
| E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research | NCT03132506 | Breast Cancer M... | patient-reporte... | 18 Years - 80 Years | University Women's Hospital Tübingen | |
| Personalised Disease Monitoring in Metastatic Breast Cancer | NCT04597580 | Breast Cancer M... Estrogen Recept... | 18 Years - | The Christie NHS Foundation Trust | ||
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer | NCT05033769 | Breast Cancer F... Neoplasm, Breas... Breast Cancer M... | Eribulin Inject... Paclitaxel inje... | 18 Years - | Institut fuer Frauengesundheit | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study | NCT05463276 | Breast Cancer Breast Neoplasm... Breast Cancer I... Breast Cancer S... Breast Cancer M... | 18 Years - 80 Years | Sindh Institute of Urology and Transplantation | ||
| Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | NCT03555877 | Breast Cancer M... | Ribociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | German Breast Group | |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer | NCT03638765 | Brain Metastase... Lung Cancer Met... Breast Cancer M... | DCVax-Direct | 18 Years - 75 Years | Northwest Biotherapeutics | |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer | NCT01919749 | Metastatic Brea... | treated recomme... | 18 Years - | Translational Drug Development | |
| A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer | NCT04197999 | HR+ Metastatic ... Breast Cancer Breast Cancer M... | GMI-1359 | 18 Years - | GlycoMimetics Incorporated | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors | NCT04659603 | Breast Cancer M... Pancreatic Carc... | tusamitamab rav... Gemcitabine | 18 Years - | Sanofi | |
| NR in Chemo-induced Peripheral Neuropathy | NCT03642990 | Chemotherapy-in... Breast Cancer M... Platinum-resist... Head and Neck C... Endometrial Can... | Nicotinamide Ri... | 18 Years - 85 Years | University of Iowa | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. | NCT04483505 | Breast Cancer M... Hormone Recepto... | Combination, Ro... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| Combination Study of SV-BR-1-GM With Retifanlimab | NCT03328026 | Breast Cancer Breast Neoplasm Metastatic Brea... Breast Cancer M... | SV-BR-1-GM Low dose cyclop... Interferon Inoc... retifanlimab | 18 Years - | BriaCell Therapeutics Corporation | |
| Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases | NCT04167605 | Breast Cancer M... Bone Metastases | Bone metastasis Breast cancer m... | 18 Years - | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | |
| Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer | NCT03086785 | Breast Cancer M... | Apatinib | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | NCT04262804 | Breast Cancer M... | Margetuximab Trastuzumab Chosen Chemothe... Chosen Chemothe... Chosen Chemothe... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | NCT06100874 | Her 2 Positive ... Breast Cancer F... Breast Cancer M... | Sacituzumab Gov... Trastuzumab Trastuzumab and... | 18 Years - | Dana-Farber Cancer Institute | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations | NCT05420779 | Breast Cancer M... | TSL-1502 capsul... TSL-1502 capsul... Investigator's ... | 18 Years - 75 Years | Tasly Pharmaceutical Group Co., Ltd | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. | NCT04483505 | Breast Cancer M... Hormone Recepto... | Combination, Ro... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| Screening For BCRL In Targeted Therapy For Breast Cancer | NCT05142800 | Lymphedema Lymphedema Arm Lymphedema of U... Lymphedema of U... Lymphedema of t... Edema Edema Arm Breast Cancer L... Breast Cancer M... Breast Cancer S... Breast Cancer | Perometer SOZO device | 18 Years - 80 Years | Massachusetts General Hospital | |
| Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer | NCT02664103 | Breast Cancer M... | Fixed-dose comb... | 18 Years - 65 Years | Sanofi | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer | NCT01919749 | Metastatic Brea... | treated recomme... | 18 Years - | Translational Drug Development | |
| Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer | NCT05609903 | Breast Cancer M... | Atezolizumab in... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer | NCT03638765 | Brain Metastase... Lung Cancer Met... Breast Cancer M... | DCVax-Direct | 18 Years - 75 Years | Northwest Biotherapeutics | |
| A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer | NCT01876251 | Breast Cancer M... | PF-03084014 PF-03084014 PF-03084014 Docetaxel Docetaxel | 18 Years - | Pfizer | |
| NR in Chemo-induced Peripheral Neuropathy | NCT03642990 | Chemotherapy-in... Breast Cancer M... Platinum-resist... Head and Neck C... Endometrial Can... | Nicotinamide Ri... | 18 Years - 85 Years | University of Iowa | |
| Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases | NCT04167605 | Breast Cancer M... Bone Metastases | Bone metastasis Breast cancer m... | 18 Years - | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
